Maravai LifeSciences (MRVI) Competitors $2.00 -0.03 (-1.24%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. NAMS, KYMR, BLTE, BHC, JANX, AAPG, ARWR, HRMY, GLPG, and CNTAShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Belite Bio (BLTE), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Ascentage Pharma Group International (AAPG), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), Galapagos (GLPG), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. NewAmsterdam Pharma Kymera Therapeutics Belite Bio Bausch Health Companies Janux Therapeutics Ascentage Pharma Group International Arrowhead Pharmaceuticals Harmony Biosciences Galapagos Centessa Pharmaceuticals Maravai LifeSciences (NASDAQ:MRVI) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has better earnings and valuation, MRVI or NAMS? Maravai LifeSciences has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.19M1.96-$119.03M-$1.02-1.96NewAmsterdam Pharma$45.56M48.00-$176.94M-$2.60-7.66 Does the MarketBeat Community favor MRVI or NAMS? Maravai LifeSciences received 36 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.43% of users gave NewAmsterdam Pharma an outperform vote while only 60.00% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformMaravai LifeSciencesOutperform Votes6360.00% Underperform Votes4240.00% NewAmsterdam PharmaOutperform Votes2796.43% Underperform Votes13.57% Does the media prefer MRVI or NAMS? In the previous week, Maravai LifeSciences had 16 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 28 mentions for Maravai LifeSciences and 12 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.48 beat Maravai LifeSciences' score of 0.06 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 1 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in MRVI or NAMS? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 0.6% of Maravai LifeSciences shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is MRVI or NAMS more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. NewAmsterdam Pharma's return on equity of 0.00% beat Maravai LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-81.13% -6.61% -3.45% NewAmsterdam Pharma N/A N/A N/A Do analysts recommend MRVI or NAMS? Maravai LifeSciences presently has a consensus price target of $6.34, suggesting a potential upside of 217.98%. NewAmsterdam Pharma has a consensus price target of $43.33, suggesting a potential upside of 117.57%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, MRVI or NAMS? Maravai LifeSciences has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. SummaryNewAmsterdam Pharma beats Maravai LifeSciences on 10 of the 18 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$507.40M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.227.3722.5818.55Price / Sales1.96242.94397.25103.00Price / Cash41.7165.8538.1834.62Price / Book0.646.486.704.26Net Income-$119.03M$143.68M$3.23B$248.39M7 Day Performance-3.62%1.79%1.26%1.27%1 Month Performance-7.64%6.68%3.75%3.85%1 Year Performance-76.31%-2.73%15.78%5.23% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences4.0319 of 5 stars$2.00-1.2%$6.34+218.0%-75.4%$507.40M$259.19M-1.22610Upcoming EarningsOptions VolumeNAMSNewAmsterdam Pharma3.1643 of 5 stars$16.26-0.5%$43.33+166.5%-12.3%$1.79B$45.56M-6.254Gap DownKYMRKymera Therapeutics1.9984 of 5 stars$27.16+4.6%$56.36+107.5%+1.9%$1.76B$47.07M-11.61170News CoveragePositive NewsBLTEBelite Bio2.8253 of 5 stars$54.69-3.0%$96.67+76.8%+51.4%$1.74BN/A-49.2710News CoveragePositive NewsBHCBausch Health Companies4.1743 of 5 stars$4.72-7.5%$7.17+51.8%-39.7%$1.74B$9.63B-39.3319,900Analyst UpgradeNews CoverageJANXJanux Therapeutics3.0291 of 5 stars$29.30-1.3%$95.25+225.1%-41.8%$1.73B$10.59M-25.0430Upcoming EarningsNews CoveragePositive NewsGap DownAAPGAscentage Pharma Group InternationalN/A$19.12+2.1%N/AN/A$1.66B$980.65M0.00600ARWRArrowhead Pharmaceuticals3.6131 of 5 stars$12.08+7.5%$41.44+243.1%-38.6%$1.66B$2.50M-2.34400Upcoming EarningsNews CoveragePositive NewsHRMYHarmony Biosciences4.8285 of 5 stars$28.50+0.1%$53.33+87.1%-4.7%$1.63B$714.73M13.51200Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGLPGGalapagos0.6174 of 5 stars$24.64-0.1%$25.33+2.8%-5.4%$1.62B$275.65M0.001,310Options VolumeCNTACentessa Pharmaceuticals2.5673 of 5 stars$12.15-1.2%$27.71+128.1%+49.7%$1.62B$6.85M-7.94200News CoveragePositive News Related Companies and Tools Related Companies NAMS Alternatives KYMR Alternatives BLTE Alternatives BHC Alternatives JANX Alternatives AAPG Alternatives ARWR Alternatives HRMY Alternatives GLPG Alternatives CNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRVI Stock Free MRVI Stock Alerts